Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott H Dickerson

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|February 18, 2006
Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitorsAlex G Waterson, Kirk L Stevens, Michael J Reno, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2011
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroupJohn C Stellwagen, George M Adjabeng, Marc R Arnone, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroupsSteven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2008
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitorsTara R Rheault, Thomas R Caferro, Scott H Dickerson, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacyStephen A Thomson, Pierette Banker, D Mark Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2009
Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitorsAlex G Waterson, Kimberly G Petrov, Keith R Hornberger, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven TumorsTara R Rheault, John C Stellwagen, George M Adjabeng, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2008
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitorsKirk L Stevens, Krystal J Alligood, Jennifer G Badiang Alberti, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinasesEdgar R Wood, Lisa M Shewchuk, Byron Ellis, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)Kyle A Emmitte, Brian J Wilson, Erich W Baum, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|February 18, 2006
Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitorsAlex G Waterson, Kirk L Stevens, Michael J Reno, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2011
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroupJohn C Stellwagen, George M Adjabeng, Marc R Arnone, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroupsSteven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2008
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitorsTara R Rheault, Thomas R Caferro, Scott H Dickerson, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacyStephen A Thomson, Pierette Banker, D Mark Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2009
Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitorsAlex G Waterson, Kimberly G Petrov, Keith R Hornberger, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven TumorsTara R Rheault, John C Stellwagen, George M Adjabeng, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2008
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitorsKirk L Stevens, Krystal J Alligood, Jennifer G Badiang Alberti, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinasesEdgar R Wood, Lisa M Shewchuk, Byron Ellis, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)Kyle A Emmitte, Brian J Wilson, Erich W Baum, et al.
Pageof 2